icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
Boston, Massachusetts
March 4-7, 2018
Back grey_arrow_rt.gif
High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies
  Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Download the PDF here
Jürgen K. Rockstroh,1 Paul E. Sax,2 Eric S. Daar,3 Sharon Walmsley,4 Kim Workowski,5 Chloe Orkin,6 Jose R. Arribas,7 Edwin DeJesus,8
David Wohl,9 Jean-Michel Molina,10 David Piontkowsky,11 Xuelian Wei,11 Hal Martin,11 Andrew Cheng,11 Erin Quirk11
1Universität Bonn, Germany; 2Brigham and Women’s Hospital, Boston, MA; 3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; 4Toronto General Hospital, Toronto, Ontario, Canada; 5Emory University, Atlanta, GA;
6Barts Health NHS Trust, The Royal London Hospital, Ambrose King Centre, London, UK; 7Hospital Universitario la Paz, Madrid, Spain; 8Orlando Immunology Center, Orlando, FL; 9University of North Carolina at Chapel Hill; 10Hôpital Saint Louis, Paris, France; 11Gilead Sciences, Inc., Foster City, CA








1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic, 2013;
2. Vemlidy [package insert].
Foster City, CA: Gilead Sciences, Inc., 4/17;
3. Vemlidy [SMPC]. Cambridge, UK: Gilead Sciences International Ltd., 2/18;
4. AIDS info. http://www.aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL.pdf. Jan 2016;
5. European AIDS Clinical Society. Guidelines. Version 9.0, Oct 2017;
6. Gunthard HF, et al. JAMA 2016;316:191-210;
7. Gallant J, et al Lancet 2017;390:2063-72; 8. Sax PE, et al. Lancet 2017;390:2073-82; 9. Boesecke C, et al. CROI 2017, abstr 580; 10. Price H, et al. PLoS One 2013;8:e68152.